Wednesday, March 30, 2016

ADI participates in NIH-NIAID sponsored meeting on Zika virus

The Zika virus epidemic that originated in other parts of the world has now made its way into US and has become a critically important research area for development of diagnostics, vaccines and therapeutics.  As a new disease that shows all the signs of becoming a global epidemic, there is an urgent need for reagents and tools that are necessary for developing methods to combat this disease.  The first Zika Virus conference (Zika Virus in the Americas: An HHS Expert Consultation to Accelerate the Development of Countermeasures) was recently concluded at North Bethesda in Maryland (Mar 28 - 29, 2016).  At this conference, Dr. Masarrat Ali had an opportunity to interact with several members of the research community to discuss and present reagents that are immediately available from ADI and understand other needs of the community in order to develop countermeasures in a timely manner.  ADI is the first company to develop reagents designed to help researchers across the world who are engaged in Zika virus research.  For additional details on these reagents, please visit

No comments:

Post a Comment